skip to main content

TKI Pancreatic Enzymes — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

EasyImmunotherapy & Targeted TherapyTKI Pancreatic EnzymesSCE Medical Oncology

A 58-year-old man on sunitinib for metastatic RCC develops asymptomatic elevated amylase (3× ULN) and lipase (4× ULN). CT abdomen is normal. He has no abdominal symptoms. What is the likely cause and management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Asymptomatic pancreatic enzyme elevation is a common class effect of VEGFR-TKIs (~5-15%) — it is usually not clinically significant and does not require treatment interruption if the patient is asymptomatic with normal imaging

Asymptomatic pancreatic enzyme elevation is a well-recognised class effect of VEGFR-TKIs (sunitinib, pazopanib, cabozantinib) occurring in 5-15% of patients. It is usually not associated with clinical pancreatitis and does not require dose modification if the patient is asymptomatic with normal imaging. This parallels the approach to asymptomatic lipase elevation with ICI (also frequently not clinically significant). Clinical pancreatitis (symptoms + imaging changes) requires different management.

Reference: BNF Sunitinib; ESMO 2024 RCC/Supportive Care